Save time and jump to the most important pieces.
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 3/13/2025 | $20.00 → $16.00 | Overweight → Equal Weight | Wells Fargo |
| 12/10/2024 | $12.00 | Underperform | Jefferies |
| 11/6/2024 | $21.00 → $13.50 | Neutral → Underperform | BofA Securities |
| 10/7/2024 | $23.00 | Neutral | UBS |
| 6/26/2024 | $25.00 | Overweight | Piper Sandler |
| 5/30/2024 | $28.00 | Outperform | Robert W. Baird |
| 5/30/2024 | $25.00 → $21.00 | Buy → Neutral | BofA Securities |
| 3/22/2024 | $20.00 | Outperform | Raymond James |
4 - Oscar Health, Inc. (0001568651) (Issuer)
4 - Oscar Health, Inc. (0001568651) (Issuer)
4 - Oscar Health, Inc. (0001568651) (Issuer)
Oscar Health, Inc. ("Oscar" or the "Company") (NYSE:OSCR), a leading healthcare technology company, announced today its financial results for the first quarter ended March 31, 2025. "Oscar reported strong financial results in the first quarter," said Mark Bertolini, CEO of Oscar Health. "We delivered continued top-line growth and bottom-line performance with significant year-over-year increases in revenue and net income. We continue to expect meaningful margin expansion this year as we deliver superior value to our members and partners." Oscar is reaffirming its full year 2025 outlook across all metrics as provided in its financial results press release dated February 4, 2025. First Qu
Oscar Health, Inc. ("Oscar" or the "Company") (NYSE:OSCR), a leading healthcare technology company, will release its first quarter 2025 financial results before the market opens on Wednesday, May 7, 2025. Management will review these results in a conference call beginning at 8:00 AM (ET). The call-in number and webcast link are as follows: Live Call: 1.855.761.5600 Conference ID: 7768132 Webcast The call will be archived and available on Oscar's investor relations website (ir.hioscar.com) following May 7, 2025 for a period of 90 days. About Oscar Health Oscar Health, Inc. ("Oscar") is a leading healthcare technology company built around a full stack technology platform and a relentless
Reports Adjusted EBITDA and Net Income Profitability for the First Time in Company History For the year ended December 31, 2024: Total Revenue of $9.2 billion, a 56.5% increase year-over-year Medical Loss Ratio of 81.7%, a 10 bps increase year-over-year SG&A Expense Ratio of 19.1%, a 520 bps improvement year-over-year Net income attributable to Oscar of $25.4 million, or $0.10 of diluted earnings per share, a $296.2 million improvement year-over-year Adjusted EBITDA of $199.2 million, an improvement of $244.5 million year-over-year Oscar Health, Inc. ("Oscar" or the "Company") (NYSE:OSCR), a leading healthcare technology company, today announced its financial results
Oscar Health, Inc. ("Oscar") (NYSE:OSCR), a leading healthcare technology company, announced that on January 22, 2024 the Compensation Committee of Oscar's Board of Directors approved the grant of employment inducement restricted stock unit awards covering an aggregate of 104,586 Class A shares of Oscar's common stock to 11 new non-executive employees of Oscar and its affiliates, to induce them to join Oscar and its affiliates. The awards generally vest quarterly over a one-year period following their vesting commencement date, subject to continued employment. The awards were granted under Oscar's 2022 Employment Inducement Award Plan as employment inducement awards pursuant to the New York
Oscar Health, Inc. ("Oscar") (NYSE:OSCR), the first health insurance company built around a full stack technology platform, today announced the appointment of two seasoned healthcare executives to round out its leadership bench and further propel its vision to refactor healthcare. Kerry Sain has joined the company as the Executive Vice President of +Oscar, effective August 14, 2023, and Steven Kelmar will join as Executive Vice President and Chief of Staff to the CEO, effective September 21, 2023. In her role, Sain oversees the go-to-market strategy for the +Oscar business and will work closely with Mario Schlosser, President of Technology and Chief Technology Officer, to continue externa
Oscar Health, Inc. ("Oscar") (NYSE:OSCR), the first health insurance company built on a full stack technology platform, today announced that Dr. Sean Martin, MD has been appointed to serve as the company's new Chief Medical Officer, effective immediately. Dr. Martin joined Oscar in 2016 and during his tenure has provided clinical leadership across a number of core clinical functions, including enterprise affordability, medical management, market performance, population health, and behavioral health. In his new role, he will be responsible for implementing Oscar's clinical capabilities and enhancing the quality of care and outcomes for its members. "Dr. Martin is an avid champion of the us
Oscar Health, Inc. ("Oscar" or the "Company") (NYSE:OSCR), a leading healthcare technology company, announced today its financial results for the first quarter ended March 31, 2025. "Oscar reported strong financial results in the first quarter," said Mark Bertolini, CEO of Oscar Health. "We delivered continued top-line growth and bottom-line performance with significant year-over-year increases in revenue and net income. We continue to expect meaningful margin expansion this year as we deliver superior value to our members and partners." Oscar is reaffirming its full year 2025 outlook across all metrics as provided in its financial results press release dated February 4, 2025. First Qu
Oscar Health, Inc. ("Oscar" or the "Company") (NYSE:OSCR), a leading healthcare technology company, will release its first quarter 2025 financial results before the market opens on Wednesday, May 7, 2025. Management will review these results in a conference call beginning at 8:00 AM (ET). The call-in number and webcast link are as follows: Live Call: 1.855.761.5600 Conference ID: 7768132 Webcast The call will be archived and available on Oscar's investor relations website (ir.hioscar.com) following May 7, 2025 for a period of 90 days. About Oscar Health Oscar Health, Inc. ("Oscar") is a leading healthcare technology company built around a full stack technology platform and a relentless
With new backing from AIX Ventures, Peter Thiel, and healthcare and AI pioneers, Ataraxis AI is positioned to rapidly bring its first offering, Ataraxis Breast, to market Ataraxis AI, the leading AI precision medicine company, today announced its $20.4 million Series A financing led by AIX Ventures with participation from Floating Point, Thiel Bio, Founders Fund, Bertelsmann Investments, and existing investors, Giant Ventures and Obvious Ventures. The round also received backing from angel investors and healthcare pioneers, including Mario Schlosser, co-founder and former CEO of Oscar Health (NYSE:OSCR), Ryan Fukushima, COO of Tempus, and others. Leading researchers from OpenAI and DeepMin
144 - Oscar Health, Inc. (0001568651) (Subject)
10-Q - Oscar Health, Inc. (0001568651) (Filer)
8-K - Oscar Health, Inc. (0001568651) (Filer)
SC 13G/A - Oscar Health, Inc. (0001568651) (Subject)
SC 13G - Oscar Health, Inc. (0001568651) (Subject)
SC 13D/A - Oscar Health, Inc. (0001568651) (Subject)
4 - Oscar Health, Inc. (0001568651) (Issuer)
4 - Oscar Health, Inc. (0001568651) (Issuer)
4 - Oscar Health, Inc. (0001568651) (Issuer)
Wells Fargo downgraded Oscar Health from Overweight to Equal Weight and set a new price target of $16.00 from $20.00 previously
Jefferies initiated coverage of Oscar Health with a rating of Underperform and set a new price target of $12.00
BofA Securities downgraded Oscar Health from Neutral to Underperform and set a new price target of $13.50 from $21.00 previously